Cancer and depression Mental and Behavioural Disorders Reaction to severe stress and adjustment disorders
Conditions
Interventions
Both groups will receive optimised usual care i.e. current practice in the Edinburgh Cancer Centre. In addition, the GP and Oncologist will be informed that the patient has major depression and asked
Sponsors
University of Edinburgh (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients attending Edinburgh Cancer Centre identified through a screening process or by referral and noted to have: 1. Definite or probable major depressive disorder on Structured Clinical Interview for Depression (SCID) interview 2. SCL-20 depression score of at least 1.72 3. A diagnosis of cancer
Exclusion criteria
Exclusion criteria: Predicted survival less than 6 months; another complicating and uncontrolled medical problem or where antidepressants are contraindicated; too ill to participate in treatment due to ongoing cancer therapy; complicating major psychiatric diagnosis or an alcohol or substance misuse problem; chronic depression; under active treatment for their depression; judged to be in need of urgent psychiatric treatment; unable to communicate adequately due to language problems or cognitive impairment; unable to travel to centre for treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The principal outcome measure will be a 50% reduction in the SCL-20 depressive symptoms score from baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary measures will be: 1. Mean depression scores from the SCL-20 2. Remission specified as an SCL-20 score of <0.75 3. The presence of major depressive disorder assessed by SCID diagnostic interview Subsidiary outcome measures will be: 1. Quality of life measured on the World Health Organisation (WHO) EQ-5D 2. EORTC-QLQ-C30 3. Anxiety measured on the 10 anxiety items of the SCL-90 4. A measure of self-efficacy, coping and social support 5. An estimate of the direct health care costs measured by case note review and patient questionnaire The outcomes will be measured at 3, 6 and 12 months | — |
Countries
United Kingdom
Outcome results
None listed